

FORM PTO-1390 (REV. 9-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 740-X01-003
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5 10/018398
INTERNATIONAL APPLICATION NO. PCT/EP00/03817	INTERNATIONAL FILING DATE 27 April 2000	PRIORITY DATE CLAIMED 12 June 1999		
TITLE OF INVENTION UTILIZATION OF A HIGHLY FLURORINATED OLIGOMERIC ALKANE IN OPHTHALMOLOGY				
APPLICANT(S) FOR DO/EO/US Udo GROSS, Dirk-Henning MENZ, Erhard KEMNITZ, Hans HOERAUF, and Karin KOBUCH				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under <u>35 U.S.C. 371</u>.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under <u>35 U.S.C. 371</u>.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). UNEXECUTED</p> <p>10. <input checked="" type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>				
<p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input checked="" type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: MARKED-UP SPECIFICATION COPIES OF REFERENCES CITED IN IDS AND COPY OF SEARCH REPORT FROM PCT/EP00/03817 POSTCARD EXPRESS MAIL CERTIFICATE </p>				

U.S. APPLICATION NO. (If known, see 37 CFR 1.6) 10/018398	INTERNATIONAL APPLICATION NO. PCT/EP00/03817	ATTORNEY'S DOCKET NUMBER 740-X01-003															
<p>21. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00</p> <p style="text-align: center;">ENTER APPROPRIATE BASIC FEE AMOUNT =</p>		CALCULATIONS PTO USE ONLY															
<p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p>		\$ 130.00															
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 15%;">CLAIMS</th> <th style="width: 25%;">NUMBER FILED</th> <th style="width: 25%;">NUMBER EXTRA</th> <th style="width: 25%;">RATE</th> <th style="width: 10%;">\$</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>8 - 20 =</td> <td>0</td> <td>x \$18.00</td> <td>\$ 0</td> </tr> <tr> <td>Independent claims</td> <td>1 - 3 =</td> <td>0</td> <td>x \$84.00</td> <td>\$</td> </tr> </tbody> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	8 - 20 =	0	x \$18.00	\$ 0	Independent claims	1 - 3 =	0	x \$84.00	\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$													
Total claims	8 - 20 =	0	x \$18.00	\$ 0													
Independent claims	1 - 3 =	0	x \$84.00	\$													
<p>MULTIPLE DEPENDENT CLAIM(S) (if applicable)</p>		+ \$280.00															
<p style="text-align: center;">TOTAL OF ABOVE CALCULATIONS =</p>		\$ 1020.00															
<p><input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.</p>		+ \$															
<p style="text-align: center;">SUBTOTAL =</p>		\$ 1020.00															
<p>Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p>		\$															
<p style="text-align: center;">TOTAL NATIONAL FEE =</p>		\$ 1020.00															
<p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</p>		\$															
<p style="text-align: center;">TOTAL FEES ENCLOSED =</p>		\$ 1020.00															
		Amount to be refunded: \$															
		charged: \$															
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 500601 in the amount of \$ 1,020.00 to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 500601. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>																	
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</p>																	
<p>SEND ALL CORRESPONDENCE TO: MARTIN FLEIT Fleit, Kain, Gibbons, Gutman & Bongini P.L. 520 Brickell Key Drive #A201 Miami, FL 33131</p> <p>Tel (305) 536-9020; Fax (305) 536-9022 Email mfleit@fleitkain.com</p>																	
<p style="text-align: right;"> SIGNATURE Martin Fleit By: Paul D. Bianco Reg# 43,500</p> <hr/> <p>NAME 16,900</p> <hr/> <p>REGISTRATION NUMBER</p>																	

10/018398
JU Rec'd PCT/PTO 12 DEC 2001

PATENT

Attorney Docket No.: 740-X01-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Udo GROSS *et al.*

Serial No.: New Patent Application; National Stage of PCT No. PCT/EP00/03817

Group Art Unit:

Filed: December 12 2001

Examiner:

For>Title: UTILIZATION OF A HIGHLY FLUORINATED OLIGOMERIC ALKANE
IN OPHTHALMOLOGY (AS AMENDED)

CERTIFICATE OF EXPRESS MAILING

PATENTS

EXPRESS "Express Mail" Mailing Label number EV053647216US

Date of Deposit December 12, 2001

I hereby certify that the attached paper(s) or fee(s) is/are being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner of Patents & Trademark, Washington D.C. 20231.



(Signature of person mailing paper or fee)

PAUL D. BIANCO

(Typed or printed name of person mailing paper or fee)